| | Business Summary | | IDEC
Pharmaceuticals
Corporation
is
a
biopharmaceutical
company
engaged
primarily
in
the
research,
development
and
commercialization
of
targeted
therapies
for
the
treatment
of
cancer
and
autoimmune
and
inflammatory
diseases.
The
company's
first
commercial
product,
Rituxan,
and
its
most
advanced
product
candidate,
ZEVALIN
(ibritumomab
tiuxetan),
are
for
use
or
intended
for
use
in
the
treatment
of
certain
B-cell
non-Hodgkin's
lymphomas
(B-cell
NHLs).
B-cell
NHLs
currently
afflict
approximately
300,000
patients
in
the
United
States.
The
Company
is
also
developing
products
for
the
treatment
of
various
autoimmune
diseases,
such
as
rheumatoid
arthritis
and
psoriasis. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | IDPH
is
primarily
engaged
in
the
commercialization
and
research
and
development
of
targeted
therapies
for
the
treatment
of
cancer
and
autoimmune
and
inflammatory
diseases.
For
the
six
months
ended
6/30/01,
revenues
rose
84%
to
$121.4
million.
Net
income
before
accounting
change
totalled
$46
million,
up
from
$19.6
million.
Results
reflect
the
commercialization
of
Rituxan
through
the
Company's
collaboration
with
Genentech,
and
increased
interest
income. | | More
from
Market Guide: Significant
Developments |
| | | | FY1999
Compensation | | Pay | Exer | |
| William Rastetter, Ph.D., 51
Chairman,
CEO, and Pres | $580K | $8.1M | Phillip Schneider, 43
CFO,
Sr. VP | -- | -- | William Rohn, 56
COO | 412K | 3.6M | Wolfgang Berthold, Ph.D., 52
Sr.
VP- Biopharmaceutical Science | -- | -- | Paul Grint, M.D.
Sr.
VP of Clinical R&D, CMO | -- | -- | | Dollar
amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/i/idph.gif)